Genetically modified islet cells as a treatment for type 1 diabetes
Per-Ola Carlsson, as principal investigator, describes the new clinical study that started in early 2024 at the Clinical Research and Development Unit's (KFUE) Phase 1 unit at Uppsala University Hospital.
In the study, patients with type 1 diabetes will be treated with islet cells (from deceased donors) that have been genetically modified to avoid detection by the patient's immune system. The hope is that this will restore the body's own insulin production without the need for immunosuppressive treatment.